AGP Executive Report
Last update: an hour agoCBD Research: A new clinical review examines cannabidiol’s potential efficacy, molecular targets, liver-drug interactions and product safety, as shoppers increasingly turn to retail CBD without clinical guidance. Trait Biosciences, meanwhile, says its CBD82S ingredient showed about 25 times the apparent half-life of conventional CBD in a lab model—a preliminary result, not proof of longer-lasting effects in people. Mental Health: A study of more than 415,000 U.S. adults found cannabis use disorder was linked to 57% higher odds of suicidal thoughts; researchers stress the finding does not show that cannabis causes them. Separate research linked frequent use with more mild psychotic-like and depressive symptoms. Product Rules: A federal hemp-THC limit due Dec. 11 threatens products sold by small businesses, while senators are pushing to keep them legal. Wisconsin’s incoming Democratic leaders also signal support for broader cannabis legalization. Medical Access: Moroccan pharmacies have begun carrying the country’s first locally made cannabis-based epilepsy medicine, while a UK pharmacy group is opening access to cannabis prescriptions.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.